| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/25/1997 | WO1997035005A2 Cftr gene regulator |
| 09/25/1997 | WO1997035004A1 Cell stimulation |
| 09/25/1997 | WO1997034998A1 Human cytokine polypeptide |
| 09/25/1997 | WO1997034997A1 Human endometrial specific steroid-binding factor i, ii and iii |
| 09/25/1997 | WO1997034930A1 Stable factor viii/ von willebrand factor complex |
| 09/25/1997 | WO1997034929A1 Process for extraction of a growth factor complex |
| 09/25/1997 | WO1997034927A1 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 09/25/1997 | WO1997034925A1 Conotoxin peptide pviia |
| 09/25/1997 | WO1997034924A1 Process and intermediates for the synthesis of lhrh antagonists |
| 09/25/1997 | WO1997034923A1 Process and intermediates for the synthesis of lhrh antagonists |
| 09/25/1997 | WO1997034922A1 Treatment of preeclampsia, eclampsia or preterm labor with calcitonin gene related peptide and related drugs |
| 09/25/1997 | WO1997034918A1 Chromatographic process for obtaining very pure cyclosporin a and related cyclosporins |
| 09/25/1997 | WO1997034914A1 Compositions for the diagnosis and treatment of chediak-higashi syndrome |
| 09/25/1997 | WO1997034913A1 Mycoplasma arthritidis superantigen |
| 09/25/1997 | WO1997034911A1 Apoptosis inducing molecule ii |
| 09/25/1997 | WO1997034644A1 Topical formulations for the treatment of nail psoriasis |
| 09/25/1997 | WO1997034639A1 Animal model for transplantation |
| 09/25/1997 | WO1997034638A1 Antisense approach to gene inhibition |
| 09/25/1997 | WO1997034633A1 Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| 09/25/1997 | WO1997034632A1 Glycosylated humanized b-cell specific antibodies |
| 09/25/1997 | WO1997034631A1 Immunoglobin-like domains with increased half lives |
| 09/25/1997 | WO1997034630A1 Peptide vaccine to prevent development of several herpes virus infections and/or atherosclerotic plaque |
| 09/25/1997 | WO1997034628A1 Milk of transgenic animals containing human alpha1-antitrypsin and use of human alpha1-antitrypsin to treat bile acid related diseases |
| 09/25/1997 | WO1997034627A2 Protection of hemopoietic cells during chemotherapy or radiotherapy |
| 09/25/1997 | WO1997034626A1 Methods for enhancing functional recovery following central nervous system ischemia or trauma |
| 09/25/1997 | WO1997034624A1 Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| 09/25/1997 | WO1997034623A1 Solid phase lipoglycopeptide library, compositions and methods |
| 09/25/1997 | WO1997034622A1 Oral cyclosporin formulations |
| 09/25/1997 | WO1997034621A1 Hla-a2.1 binding peptides and their uses |
| 09/25/1997 | WO1997034620A1 Peptide inhibitors of neurotransmitter secretion by neuronal cells |
| 09/25/1997 | WO1997034619A1 Methods of treating herpes or chlamydia |
| 09/25/1997 | WO1997034618A1 Administration of polypeptide growth factors following central nervous system ischemia or trauma |
| 09/25/1997 | WO1997034617A1 Hla binding peptides and their uses |
| 09/25/1997 | WO1997034616A1 A method for periodontal disease treatment |
| 09/25/1997 | WO1997034604A1 4-spiroindoline piperidines promote release of growth hormone |
| 09/25/1997 | WO1997034586A2 Device and method for treating ophthalmic diseases |
| 09/25/1997 | WO1997034584A1 Composite gel microparticles as active principle carriers |
| 09/25/1997 | WO1997034581A1 Method for solubilising hydrophylic materials (e.g. proteins) in a hydrophobic solvent |
| 09/25/1997 | WO1997034567A2 Method for treating huntington's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
| 09/25/1997 | WO1997034501A1 Folate receptor-directed metalloproteases and methods for using same |
| 09/25/1997 | WO1997034473A1 Craf1 (traf-3) isoforms and uses thereof |
| 09/25/1997 | WO1997034472A1 Methods for inducing immune responsiveness in a subject |
| 09/25/1997 | WO1997031116A3 Recombinant ribonuclease proteins |
| 09/25/1997 | WO1997031112A3 Compounds and related methods for modulating potassium ion channels and assays for such compounds |
| 09/25/1997 | WO1997030082A3 Antifungic and antibacterial peptide |
| 09/25/1997 | WO1997027220A3 Substrates and inhibitors for cysteine protease ich-1 |
| 09/25/1997 | WO1997020031A3 Rna polymerase ii carboxyl terminal domain-derived peptides |
| 09/25/1997 | WO1997019113A3 Monoclonal antiidiotypic antibodies (ab2) and uses thereof |
| 09/25/1997 | WO1997017446A3 HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF |
| 09/25/1997 | WO1997012043A3 Hcv ns3 protein fragments having helicase activity and improved solubility |
| 09/25/1997 | DE19611094A1 Chromatographisches Verfahren zur Gewinnung von hochgereinigtem Cyclosporin A und verwandten Cyclosporinen Chromatographic method for the recovery of highly purified cyclosporin A and related cyclosporins |
| 09/25/1997 | CA2283633A1 Peptide vaccine to prevent development of several herpes virus infections and/or atherosclerotic plaque |
| 09/25/1997 | CA2250222A1 Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| 09/25/1997 | CA2249997A1 Chemokine alpha 2 |
| 09/25/1997 | CA2249995A1 Chemokine alpha 3 |
| 09/25/1997 | CA2249585A1 Animal model for transplantation |
| 09/25/1997 | CA2249551A1 A kinase capable of site-specific phosphorylation of i.kappa.b.alpha. |
| 09/25/1997 | CA2249449A1 Mycoplasma arthritidis superantigen |
| 09/25/1997 | CA2249412A1 Methods for inducing immune responsiveness in a subject |
| 09/25/1997 | CA2249368A1 Administration of polypeptide growth factors following central nervous system ischemia or trauma |
| 09/25/1997 | CA2249323A1 Solid phase lipoglycopeptide library, compositions and methods |
| 09/25/1997 | CA2249274A1 Composite gel microparticles as active principle carriers |
| 09/25/1997 | CA2249251A1 Human cytokine polypeptide |
| 09/25/1997 | CA2249196A1 Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| 09/25/1997 | CA2249195A1 Immunoglobin-like domains with increased half lives |
| 09/25/1997 | CA2249179A1 Fibroblast growth factor homologous factor-3 (fhf-3) and methods of use |
| 09/25/1997 | CA2248977A1 Topical formulations for the treatment of nail psoriasis |
| 09/25/1997 | CA2248868A1 Apoptosis inducing molecule ii |
| 09/25/1997 | CA2248843A1 Process for extraction of a growth factor complex |
| 09/25/1997 | CA2248659A1 Hla binding peptides and their uses |
| 09/25/1997 | CA2248629A1 Enzymes combinations for destroying proliferative cells |
| 09/25/1997 | CA2248614A1 Human cell death-associated protein |
| 09/25/1997 | CA2248351A1 Method for solubilising hydrophylic materials (e.g. proteins) in a hydrophobic solvent |
| 09/25/1997 | CA2248136A1 Human endometrial specific steroid-binding factor i, ii and iii |
| 09/25/1997 | CA2242342A1 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 09/25/1997 | CA2220914A1 Method for treating huntington's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
| 09/24/1997 | EP0796913A2 GDP dissociation stimulating protein, brain-specific nucleosome assembly protein, skeletal muscle specific ubiquitin-conjugating enzyme, cell proliferation protein, phosphatidylinositolkinase, nel related proteins |
| 09/24/1997 | EP0796867A1 Peptide, bronchodilator and blood flow ameliorant |
| 09/24/1997 | EP0796866A1 Antithrombotic diamides |
| 09/24/1997 | EP0796623A2 Pharmaceutical preparation for the treatment of blood coagulation disorders |
| 09/24/1997 | EP0796622A2 The use of a gonadotropin releasing hormone analog or mime thereof for the preparation of a pharmaceutical composition as an adjunctive for the invasive treatment of carcinomas |
| 09/24/1997 | EP0796342A2 Genetic basis of factor xiii activity |
| 09/24/1997 | EP0796341A2 Identification of genes |
| 09/24/1997 | EP0796339A1 Packaging cell lines for generation of high titers of recombinant aav vectors |
| 09/24/1997 | EP0796334A1 Tumor-specific antibody fragments, fusion proteins, and uses thereof |
| 09/24/1997 | EP0796332A1 Neisseria meningitidis subunit tbp2 |
| 09/24/1997 | EP0796331A2 Production and administration of high titer recombinant retroviruses |
| 09/24/1997 | EP0796330A1 Rantes peptide and fragments and compositions comprising it for treatment of inflammation |
| 09/24/1997 | EP0796326A1 Vaccine and antitoxin for treatment and prevention of c. difficile disease |
| 09/24/1997 | EP0796325A1 Human vascular ibp-like growth factor |
| 09/24/1997 | EP0796324A1 Polypeptide with reduced allergenicity |
| 09/24/1997 | EP0796323A1 Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases |
| 09/24/1997 | EP0796322A1 Production and use of human and plant methyltransferases |
| 09/24/1997 | EP0796321A1 E2 binding proteins |
| 09/24/1997 | EP0796320A1 Human dna ligase iii |
| 09/24/1997 | EP0796280A2 Murine monoclonal anti-idiotype antibody 3h1 |
| 09/24/1997 | EP0796278A1 Disulphide-cyclo- h-cys-glu-gln-tyr-cys-oh], and its use in blood-clotting disorders |
| 09/24/1997 | EP0796276A1 Gradual modification, super-agonists and antagonists of signal-proteins and peptides |
| 09/24/1997 | EP0796275A2 Genes and gene products for use in the diagnosis of degenerative nerve damage |
| 09/24/1997 | EP0796273A1 Variants of human papilloma virus antigens |